Skip to main content

Featured

Understanding Your TFSA Contribution Room in 2026

A Tax‑Free Savings Account (TFSA) is one of Canada’s most flexible and powerful savings tools, but figuring out your exact contribution room can feel like solving a puzzle. A clear breakdown makes it much easier. How TFSA Contribution Room Works Your available room is made up of three parts: Annual TFSA limit for the current year Unused contribution room from previous years Withdrawals from previous years (added back the following January) For 2026, the annual TFSA limit is $7,000 . Step‑by‑Step: How to Calculate Your Room Use this simple formula: [ \text{TFSA Room} = \text{Unused Room from Prior Years} + \text{Current Year Limit} + \text{Withdrawals from Last Year} ] A quick example: Unused room from past years: $18,000 2026 limit: $7,000 Withdrawals made in 2025: $4,000 [ \text{Total Room} = 18,000 + 7,000 + 4,000 = 29,000 ] That means you could contribute $29,000 in 2026 without penalty. A Few Helpful Notes Over‑contributions lead to penalties, so it’s worth...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment